Carcinoma of Unknown Primary Site: A Mini-Review on Chemotherapy and the Expectation for Treatment with Nab-Paclitaxel Plus Carboplatin

Yasuko Ichikawa, Ryosuke Ochiai, Terunobu Haruyama, Masashi Ishihara, Yoko Fukasawa, Takahiko Sakamoto, Shigeru Tanzawa, Takeshi Honda, Shuji Ota, Kiyotaka Watanabe, Nobuhiko Seki*

Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine 2-11-1, Kaga, Itabashi-ku, Tokyo 173-8606, Japan

*Corresponding author: Nobuhiko Seki, M.D., Ph.D, Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo 173-8606, Japan, Tel: +81-3-3964-1211; Fax: +81-3-3964-9177; E-mail: nseki@med.teikyo-u.ac.jp

Received: April 22, 2019; Accepted: May 23, 2019; Published: May 27, 2019

Abstract

Cancer of unknown primary site (CUP) is a heterogeneous group of cancers with widely varying natural histories and biological characteristics for which the anatomical site of origin remains occult after detailed investigations. Several clinicopathological subsets with favorable prognosis have been identified. CUP presents a clinical situation quite difficult to manage due to the absence of a standard of care for the initial therapeutic approach, as well as an impossibility to include these cases in randomized clinical trials. Historically, a “favorable subset” designation was made based on a presentation that overwhelmingly suggested a specific primary origin. Although several clinicopathologic subsets with favorable prognosis have been identified, most patients do not fit into any of these subsets. CUP is often associated with a poor prognosis, as patients are usually treated with a non-selective empirical therapy. During the past 3 decades, some phase II trials of platinum-based combination regimens containing newer cytotoxic agents (taxanes, gemcitabine, irinotecan, etc.) resulted in response rates of 20%–60% and median survivals of 6–11 months. In these trials, taxane-based regimens showed better responses and longer survivals. Therefore, taxane–platinum regimens as empiric chemotherapy are widely used for these patients. In the current paper, we summarize both the therapeutic challenges for patients with CUP as well as the current available therapeutic options, and introduce our trial currently in progress for this population.

Keywords: cancer of unknown primary site, taxane, carboplatin, nab-paclitaxel

Introduction

Definition and characteristics of cancer of unknown primary site

Cancer of unknown primary site (CUP) is a collective term for cancers for which metastatic sites have been identified, but the primary site has not, despite detailed investigations. CUP, which has various origins, is a heterogeneous group of various cancers [1,2]. While CUP is estimated to account for 1% to 5% of all cancer cases, the reported incidence may change due to advances in diagnostic technology [3,4]. Anatomically identified common origins are pancreas, biliary tract, and lung, but even autopsy fails to reveal the site of origin in 20% to 50% of patients [5,9]. CUP generally has a poor prognosis, partly due to metastases to multiple organs at the time of diagnosis in more than half of patients, with an estimated median survival time (MST) of 6 to 9 months [10,11]. CUPs, which have common biological characteristics such as latent rapid progression and dissemination regardless of origin, were initially distinguished from conventional cancers. However, chromosomal abnormality, microvascularization, aneuploidy, and genetic abnormality are not specific to CUP [12-19]. In addition, it is said...
that genetic mutation is detected in as low as 18% of patients with CUP [20]. Accordingly, CUP retains the characteristics of cancer involving the putative organ of origin, and may therefore be optimally treated if managed like cancer involving the putative organ of origin.

Among CUPs, seven subsets of cases with favorable prognosis for which appropriate treatment is available to some extent have been identified, as listed below [2]. These CUPs, as well as sarcoma, malignant lymphoma, and malignant melanoma, have been excluded from recent clinical studies on CUP.

i. Females who have adenocarcinoma with evidence of only enlarged axillary lymph nodes (treated as axillary lymph node-positive breast cancer)

ii. Females who have adenocarcinoma with evidence of only peritoneal dissemination (ascites) and increased CA125 (treated as ovary cancer)

iii. Patients with squamous cell carcinoma with evidence of only enlarged neck lymph nodes (treated as head and neck cancer)

iv. Patients with squamous cell carcinoma with evidence of only enlarged groin lymph nodes (resection, radical radiation therapy, and/or radical chemoradiotherapy)

v. Males aged 50 years or less who have lesion(s) in the midline (treated with cisplatin-based chemotherapy as germ cell tumor)

vi. Patients who have histological characteristics of neuroendocrine tumor of unknown primary site (advanced well-differentiated neuroendocrine tumor of midgut origin is treated with somatostatin analogues, advanced well-differentiated neuroendocrine tumor of pulmonary or gastrointestinal origin is treated with everolimus, and poorly-differentiated neuroendocrine carcinoma is treated as small cell lung cancer)

vii Males who have adenocarcinoma with evidence of only osteoblastic bone metastasis and increased PSA (treated as prostate cancer)

Approaches to cancer of unknown primary site

While approaches to CUP have changed due to advancements in diagnostic imaging as well as developments in immunostaining and molecular profiling, much remains unknown and continuous attempts are being made to develop treatments even in the era of individualized medicine.

Changes in our understanding of CUP have come about over the past three decades [21]. Initially, the category of CUP was established due to advances in diagnostic imaging. Subsequently, among CUPs, seven subsets with favorable prognosis were identified based on histopathological findings, patterns of involved organs, and serum marker findings [2]. More recently, new immunohistochemical markers and advances in pathological diagnostic tools, as well as their combinations, have helped in identifying the primary site more accurately, and proteomics and genetic tools are currently studied [13,14, 22-34].

Changes in chemotherapy for cancer of unknown primary site

Chemotherapy, a systemic therapy, is generally indicated for CUP, for which only metastatic sites are detected. In general, therefore, surgery or radiation therapy, which is locally applied, is used in combination with chemotherapy as part of multidisciplinary treatment or is not indicated at all. To date, many clinical studies of chemotherapy in CUP have been reported (Table 1). However, no large phase III studies, including comparative studies of chemotherapy versus best supportive care, have been reported. In addition, the previous clinical studies were mostly conducted in narrowly defined CUP, that is, adenocarcinoma, undifferentiated carcinoma, and epithelial tumor such as squamous cell carcinoma, while excluding sarcoma, malignant lymphoma, and malignant melanoma.

Chemotherapy for CUP was attempted with 5-fluouracil (5-FU), cyclophosphamide, and doxorubicin in the 1980s, but failed to achieve great success, with a response rate of less than 40%, an MST of less than 9 months, and a 1-year survival rate of less than 25% [35-38]. Later, cisplatin was introduced, but a very small comparative study failed to verify the superiority of cisplatin, leading to no conclusion on whether or not to include cisplatin in the treatment regimen [37,38,40]. In the 1990s, new drugs, including taxanes, gemcitabine, irinotecan hydrochloride, and vinorelbine, were introduced for many cancers, and many phase II studies of these drugs primarily in combination with platinum were conducted in CUP [39,41-63]. The results, although from phase II studies, were much more favorable than those of the previous drugs, as shown by response rates of 20% to 60%, MST of more than 12 months in some studies, and 1-year survival rates of 25% to 50%. Since taxanes combined with platinum consistently produced favorable results, combination therapy with carboplatin and paclitaxel is widely used in current clinical settings.

Other phase II studies had been conducted using various regimens, including non-platinum combination regimens and at least triple therapy, but mostly did not produce satisfactory results [40-68]. Since at least triple therapy is especially associated with more intense adverse events than dual therapy, platinum-based dual therapy may be appropriate chemotherapy for CUP in clinical settings.

Clinical studies in cancer of unknown primary site

In a search of ClinicalTrials.gov for “cancer of unknown primary site” or “cancer of unknown origin,” more than 100 clinical studies were identified as of March 2019 [69]. Among all, the study with identifier NCT03278600 is an ongoing randomized study identifying the primary site through 90 genetic analyses and...
Table 1. Main previous clinical studies in cancer of unknown primary site.

| Authors               | Publication | Regimen                  | n  | Phase | RR (%) | MST (months) | 1-year survival rate (%) |
|-----------------------|-------------|--------------------------|----|-------|---------|--------------|--------------------------|
| Woods RL et al. [35]  | 1980        | CFM+MTX+5-FU DXR+MMC     | 22 | r     | 5       | 1.8          | 4.5                      | 18* 42*                   |
|                       |             | DXR+MMC                  | 25 |       |         |              |                          |                          |
| Goldberg RM et al. [36]| 1986        | DXR+MMC+5-FU             | 45 | P2    | 30      | 9.4          | 44                       |
| Eagan RT et al. [37]  | 1987        | DXR+MMC                  | 28 | r     | 14      | 4.6          | 5.5                      | 19 12                     |
| Milliken ST et al. [38]| 1987        | DXR+MMC                  | 48 | r     | 42      | 4.5          | 6.3                      | 20* 18*                   |
| Hainsworth JD et al. [39]| 1997        | CBDCA+PTX+VP-16          | 71 | P2    | 48      | 13.4         | 50                       |
| Falkson CI et al. [40]| 1998        | CDDP+Epi+MMC MMC         | 41 | r     | 50      | 9.4          | 5.4                      | 38* 26*                   |
| Greco FA et al. [41]  | 2000        | CDDP+DTX CBDCA+DTX       | 26 | P2    | 26      | 8           | 42                       | 29                        |
| Voog E et al. [42]    | 2000        | CDDP+VP-16               | 25 | P2    | 32      | 8           |                          |
| Parnis FX et al. [43] | 2000        | CDDP+FU+EPI              | 43 | P2    | 23      | 5.8          |                          |
| Briasoulis E et al. [44]| 2000        | CBDCA+PTX                | 77 | P2    | 39      | 13          | 50*                      |
| Dowell JE et al. [45] | 2001        | CBDCA+VP-16 PTX+5-FU+Iv | 17 | rP2   | 19      | 6.5          | 8.4                      | 30* 30*                   |
| Guardiola E et al. [46]| 2001        | CDDP+DXR+CFM             | 22 | P2    | 50      | 10.7         | 25                       |
| Culine S et al. [47]  | 2002        | CDDP+VCM+CDDP+VP-16      | 82 | P2    | 39      | 10           |                          |
| Greco FA et al. [48]  | 2002        | CBDCA+PTX+GEM            | 113| P2    | 25      | 9           | 42                       |
| Culine S et al. [49]  | 2003        | CDDP+GEM CDDP+CPT-11     | 39 | rP2   | 55      | 8           | 6                        |
| Balaña C et al. [50]  | 2003        | CDDP+GEM+VP-16           | 30 | P2    | 37      | 7.2          | 27                       |
| Park YH et al. [51]   | 2004        | CDDP+PTX                 | 37 | P2    | 42      | 11           | 38                       |
| Piga A et al. [52]    | 2004        | CBDCA+DXR+VP-16          | 102| P2    | 27      | 9           | 35                       |
| El-Rayas BF et al. [53]| 2005        | CBDCA+PTX                | 22 | P2    | 23      | 6.5          | 27                       |
| Palmieri S et al. [54] | 2006        | CDDP+GEM+PTX CDDP+GEM+VNR| 33 | rP2   | 49      | 9.6          | 13.6                     | 30* 55*                   |
| Pittman KB et al. [55] | 2006        | CBDCA+GEM                | 51 | P2    | 31      | 7.8          | 26                       |
| Hainsworth JD et al. [56]| 2007        | Erl+Bev                  | 51 | P2    | 10      | 7.4          | 33                       |
| Schneider BJ et al. [57]| 2007        | CBDCA+GEM+Cape           | 33 | P2    | 39      | 7.6          | 36                       |
| Pentheroudakis G et al.[58]| 2008        | CBDCA+DTX                | 23 | P2    | 32      | 16           |                          |
| Briasoulis E et al. [59]| 2008        | OX+CPT-11                | 47 | P2    | 13      | 9.5          | 40                       |
| Huebner G et al. [60] | 2009        | CBDCA+PTX+GEM+VNR        | 46 | rP2   | 24      | 11           | 7                        | 38 29                     |
| Yonemori K et al.v[61]| 2009        | CBDCA+CPT-11             | 45 | P2    | 42      | 12.2         | 44                       |
| Hainsworth JD et al. [62]| 2009        | CBDCA+PTX+Bev+Erl        | 49 | P2    | 53      | 12.6         | 2y-SR 27                 |
| Mukai H et al. [63]   | 2010        | CDDP+DTX                 | 45 | P2    | 65      | 11.8         | 50*                      |
| Hainsworth JD et al. [64]| 2010        | CBDCA+PTX+VP-16 GEM+CPT-11| 93 | P3    | 18      | 7.4          | 8.5                      | 2y-SR 15 2y-SR 18         |
| Holtan SG et al. [65] | 2012        | GEM+CPT-11               | 31 | P2    | 12      | 7.2          |                          |
| Gross-Goupil M et al. [66]| 2012        | CDDP+GEM                 | 27 | rP2   | 19      | 11           | 8                        | 46 35                     |
| Tsuya A et al. [67]   | 2013        | CDDP+S-1                 | 46 | P2    | 41      | 17.4         | 67                       |
| Shin DY et al. [68]   | 2016        | FOLFOX6                  | 23 | P2    | 35      | 9.5          | 50*                      |

r: Randomized study with unspecified development phase  
P2: Phase 2; rP2: Randomized phase 2; RR: Response rate; MST: Median survival time; 2y-SR: 2-year survival rate  
*Estimated based on survival curve in original article  
Blank: Not specified in original article
molecular profiling to compare standard chemotherapy for the putative organ of origin and general chemotherapy for CUP [70]. Currently, stereotypical chemotherapy is administered for CUPs regardless of characteristics of individual cancers. This study is designed to identify the organ of origin for each cancer not through morphological analysis, but through genetic analysis, and to treat the cancer accordingly. It is a very interesting clinical study in that a so-called precision medicine is introduced to treat the putative organ of origin.

On the other hand, combination therapy with carboplatin and paclitaxel, which is widely used in current clinical settings, has the following problems: need of premedication with steroid or antihistaminic to prevent hypersensitivity to paclitaxel; long duration of intravenous infusion; contraindicated in patients with hypersensitivity to ethanol, which is contained in a vehicle for paclitaxel; and intense and frequent peripheral nerve disorder. In recent years, nab-paclitaxel has been developed to resolve these problems. Consequently, high expectations are placed on combination therapy with carboplatin and nab-paclitaxel in clinical settings.

**Outcome of treatment of cancers with nab-paclitaxel**

Nab-paclitaxel, which is nanoparticle paclitaxel bound to human serum albumin, is a taxane, and paclitaxel, the active ingredient, exhibits antitumor activity by promoting microtubule protein polymerization and inhibiting microtubule protein depolymerization [71,72]. Nab-paclitaxel, which is manufactured by binding highly water-insoluble paclitaxel to human serum albumin and then lyophilizing albumin-bound paclitaxel, can be administered as a suspension in normal saline without using conventional vehicles for paclitaxel (polyoxyethylene castor oil and ethanol).

Four clinical studies described below showed higher efficacy of nab-paclitaxel than that of conventional paclitaxel. In a non-Japanese phase III comparative study in patients with metastatic breast cancer (Study CA012-0), the response rate was 24% (55/229 subjects) in the nab-paclitaxel group and 11% (25/225 subjects) in the paclitaxel group (p<0.001) [73]. In a Japanese single-arm phase II study in patients with advanced/recurrent gastric cancer who received second-line treatment (Study J-0200), the response rate in the nab-paclitaxel group was 28% (15/54 subjects), which exceeded an expected response rate of 25% [74]. In a global phase III study in patients with advanced small-cell lung cancer (Study CA031), the response rate was 33% (170/521 subjects) in the nab-paclitaxel group and 25% (132/531 subjects) in the paclitaxel group (combined with carboplatin in both groups) (p=0.005). In a global phase III study in patients with metastatic pancreatic cancer, gemcitabine used in combination with nab-paclitaxel significantly improved overall survival time, compared with gemcitabine alone (8.5 months vs. 6.7 months, HR 0.72, p<0.001) [75,76].

Nab-paclitaxel has thus been demonstrated to be effective for various cancers, but has not been studied in CUP. Nonetheless, nab-paclitaxel, which is effective for various solid tumors of different origins, may likely be effective for CUP of unknown origin.

We are therefore conducting a single-arm phase II study to determine the efficacy of combination therapy with nab-paclitaxel and carboplatin for untreated CUP. The protocol of this study is summarized below. If the study demonstrates high efficacy and tolerability of nab-paclitaxel plus carboplatin, this combination is highly expected to be more widely used than combination therapy with carboplatin and paclitaxel, which is currently used in clinical settings.

**Protocol digest**

"Efficacy and safety of nab-paclitaxel plus carboplatin in patients with carcinoma of unknown primary site"

**Study objective**

To determine the efficacy and tolerability of combination therapy with nab-paclitaxel and carboplatin in untreated cancer of unknown primary site.

**Study design**

Single-arm phase II study

**Endpoints**

Primary endpoint: 1-year survival rate

Secondary endpoints: overall survival time, progression-free survival time, response rate, safety, quality of life (QOL)

**Inclusion criteria**

Patients who meet all of the following criteria are eligible to participate in the study:

i. Histological or cytological evidence of metastatic tumor and unknown primary site

ii. Chemotherapy-naïve

iii. Aged 20 years or more at the time of informed consent

iv. PS: 0-2

v. Preserved organ functions as evidenced by neutrophil count $\geq 1500$/mm$^3$, hemoglobin $\geq 9.0$ g/dL, platelet count $\geq 100,000$/mm$^3$, total bilirubin $\leq 1.5$ mg/dL, AST/ALT $\leq 2.5 \times$ upper limit of normal (ULN), and serum creatinine $\leq 1.5 \times$ ULN (based on data collected within 14 days before enrollment)

vi. Written informed consent directly provided by the patient
Exclusion criteria
Patients who meet any of the following criteria are not eligible to participate in the study:

(1) Among patients with CUP, there may be a population of those with favorable prognosis for whom standard therapy is available. Therefore, the following patient groups are excluded from the study:

i. Females who have adenocarcinoma of unknown primary site with evidence of only enlarged axillary lymph nodes
ii. Females who have adenocarcinoma with evidence of only peritoneal dissemination (ascites)
iii. Patients who have squamous cell carcinoma with evidence of only enlarged neck lymph nodes
iv. Patients who have squamous cell carcinoma with evidence of only enlarged groin lymph nodes
v. Patients who have characteristics of germ cell tumor or neuroendocrine tumor
vi. Males who have only osteosclerotic bone metastasis and increased PSA, a tumor marker in serum or tumor

(2) Patients for whom radical surgery or radical radiation is indicated
Palliative radiation therapy is acceptable, including radiation therapy for bone metastasis applied to 30% or less of hematopoietic bone marrow.

(3) Patients with serious infection or serious other concurrent disease (e.g., gastrointestinal hemorrhage, heart disease)
These diseases are acceptable if treated appropriately and considered to be inactive.

(4) Patients with central nervous symptom due to brain metastasis at enrollment

(5) Patients with evidence of interstitial pneumonia or pulmonary fibrosis

(6) Patients who have undergone bone marrow transplantation

(7) Patients who have undergone peripheral blood stem cell transplantation

(8) Patients with a history of clinically significant serious drug allergy

(9) HBsAg-positive patients

(10) Pregnant women, lactating women, women who may be pregnant, and patients who wish to become pregnant

(11) Fertile males who do not agree to use contraceptives during the study

(12) Patients with inadequately controlled diabetes mellitus

(13) Patients who, in the opinion of the investigator or subinvestigator, are not appropriate for the study

Treatment
Nab-paclitaxel will be administered as an intravenous infusion over 30 minutes at a dose of 100 mg/m2 once daily, followed by at least 6 days of washout. Treatment will be repeated, with one course consisting of once-weekly administration for three consecutive weeks. Carboplatin, dissolved in 250 mL of 5% glucose solution or normal saline, will be administered as an intravenous infusion over 60 minutes once daily after intravenous infusion of nab-paclitaxel, followed by at least 20 days of washout. Treatment will be repeated, with one course consisting of single administration in three weeks. Day 1 of each course will be started according to the following criteria:

i. PS: 0-2
ii. Neutrophil count ≥ 1,000/mm3
iii. Platelet count ≥ 50,000/mm3
iv. Peripheral nerve disorder ≤ CTCAE Grade 2

Treatment with nab-paclitaxel on day 8 or 15 will be started according to the same criteria. Treatment on day 1, 8, or 15 will be skipped if the treatment criteria are not met. Protocol treatment will be discontinued according to the following criteria:

i. Obvious tumor growth or a new lesion is detected.
ii. The next course cannot be resumed within 21 days after the original scheduled date due to unfavorable test value or subject condition
iii. Treatment cannot be continued due to a serious adverse event.
iv. The patient requests withdrawal from the study.

Rationale for sample size selection
Given 1-year survival rates of 25% to 50% reported with conventional combination chemotherapy with platinum and taxane, the expected and threshold 1-year survival rates are assumed to be 50% and 25%, respectively, in this study. Based on this assumption, 25 subjects are needed at a one-sided significance level of 5% with a statistical power of 80%. Allowing for enrollment of dropouts and ineligible patients, a total target sample size of 30 patients is determined.

Abbreviations
CUP: cancer of unknown primary site; MST: median survival time; PSA: Prostate Specific Antige; “QOL: quality of life; “PS: Performance status; AST: Aspartate transaminase; ALT: alanine aminotransferase; ULN: upper limit of normal; CTCAE: Common Terminology Criteria for Adverse Events

Conflicts of Interest
Dr. Seki reports personal fees from Taiho Pharmaceutical during the conduct of the study; personal fees from Chugai Pharma, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Lilly Japan, personal fees from Daiichi Sankyo, personal fees from Ono Pharmaceutical, personal fees from
References

1. Briasoilis E, Tolis C, Bergh J, et al. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol. 2005; 16 Suppl 1: 175-6.

2. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, editors. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2008: 2363-87.

3. Muir C. Cancer of unknown primary site. Cancer. 1995 Jan 1; 75 (1 Suppl): 353-6.

4. Abbruzzese JL, Abbruzzese MC, Hess KR, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994; 12: 1272-80.

5. Nystrom JS, Weiner JM, Heffelfinger-Juttner J, et al. Metastatic and histologic presentations in unknown primary cancer. Semin Oncol. 1977; 4: 53-8.

6. Mayordomo JI, Guerra JM, Guijarro C, et al. Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori. 1993; 79: 321-4.

7. Hillen HF. Unknown primary tumours. Postgrad Med J. 2000; 76: 690-3.

8. Bugat R, Bataillard A, Lesimple T, et al. Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer. 2003; 89 Suppl 1: S59-66.

9. Blaszky H, Hartmann A, Bjernsson J. Cancer of unknown primary: clinicopathologic correlations. APMIS. 2003; 111: 1089-94.

10. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med. 1993; 329: 257-63.

11. Pavlidis N, Briasoilis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003; 39: 1990-2005.

12. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med. 2008; 132: 384-96.

13. DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Semin Diagn Pathol. 2000; 17: 184-93.

14. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005; 11: 3766-72.

15. Pavlidis N, Briasoilis E, Bae M, et al. Overexpression of C-myc, Ras and C-erbB-2 oncproteins in carcinoma of unknown primary origin. Anticancer Res. 1995; 15: 2563-7.

16. Briasoilis E, Tsokos M, Fountzilas G, et al. Bcl2 and p53 protein expression in metastatic adenocarcinoma of unknown primary origin: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013; 31: 217-23.

17. Hainsworth JD, Mettetal S, Tattersall MH, et al. Multifactorial approach to determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev. 2001; 10: 77-82.

18. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med. 2008; 132: 384-96.

19. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007; 43: 2026-36.

20. Bloom G, Yang IV, Boulware D, et al. Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol. 2004; 164: 9-16.

21. Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med. 2014; 371: 757-65.

22. Rubin BP, Skarin AT, Pissik E, et al. Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev. 2001; 10: 77-82.
To cite this article: Ichikawa Y, Ochiai R, Haruyama T, et al. Carcinoma of Unknown Primary Site: A Mini-Review on Chemotherapy and the Expectation for Treatment with Nab-Paclitaxel Plus Carboplatin. Japan Journal of Medicine. 2019: 2:3.

© Ichikawa Y, et al. 2019.